Arqule, Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
18
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 10, 2027The maintenance fee for Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same (US 9,180,099) comes due May 10, 2027. Unpaid by Nov 10, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,377,927 | Compositions and methods for treatment of cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 7,812,051 | Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential In force · From the USPTO record | In force | From the USPTO record | |
| US 7,932,279 | Substituted tetrazole compounds and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,304,425 | Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 7,790,765 | Hydroxy sulfonate of quinone compounds and their uses In force · From the USPTO record | In force | From the USPTO record | |
| US 7,713,969 | Compositions and methods for treatment of cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 8,614,228 | Quinone prodrug compositions and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 8,513,292 | Compositions and methods for the treatment of cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 8,049,005 | Substituted tetrahydropyrazolo-pyrido-azepine compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 8,293,892 | Substituted tetrahydropyrazolo-pyrido-azepine compounds In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 55: 1 patent in force now held by others · 31 lapsed for an unpaid fee · 23 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 19 no status recorded